AF
STRO icon

Advisornet Financial’s Sutro Biopharma STRO Stock Holding History

Advisornet Financial’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$325 – 2362
2025
Q1 		$325 Hold
50
– – ﹤0.01% 2028
2024
Q4 		$920 Hold
50
– – ﹤0.01% 1697
2024
Q3 		$1.73K Hold
50
– – ﹤0.01% 1787
2024
Q2 		$1.47K Hold
50
– – ﹤0.01% 1701
2024
Q1 		$2.83K Buy
+50
New +$2.21K ﹤0.01% 1551

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Advisornet Financial's STRO Position: Q2 2025 in Review

Advisornet Financial sold out of Sutro Biopharma (STRO) in Q2 2025, closing a stake of 50 shares — an estimated $325 sold.

Advisornet Financial first reported a position in STRO in Q1 2024 and held it in 5 quarters. The position peaked at $2.83K in Q1 2024. 99 funds tracked by Wall St. Rank hold STRO as of Q2 2025.

  • Advisornet Financial reported no remaining Sutro Biopharma position as of Q2 2025 after selling out during the quarter.
  • Advisornet Financial sold 50 Sutro Biopharma shares in Q2 2025, an estimated $325.
  • Advisornet Financial first reported a position in Sutro Biopharma in Q1 2024 and held it in 5 quarters.
  • Advisornet Financial's Sutro Biopharma position peaked at $2.83K in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2025.

Based on Advisornet Financial's 13F filing for Q2 2025, filed 14 Jul 2025.